These studies showed that PARP inhibition, alone or in combination with the TNF-α inhibitor thalidomide, reduced the severity of two different models of arthritis, potassium peroxochromate-induced arthritis and the collagen-induced arthritis (CIA) [30, 31]. Here, TNF is linked to arthritic joint disease.